Print

Search Results: Treatment + Prostate Cancer + Newly Diagnosed (2 results)

SWOG S2210: Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/286/swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.


A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach

Treatment

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit  the E-Reach registration page


Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + Newly Diagnosed + test
11 results

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
NCT ID: NCT05496959 (https://classic.clinicaltrials.gov/show/NCT05496959)

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT ID: NCT05806515 (https://classic.clinicaltrials.gov/show/NCT05806515)

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT ID: NCT04989946 (https://classic.clinicaltrials.gov/show/NCT04989946)

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT ID: NCT05155046 (https://classic.clinicaltrials.gov/show/NCT05155046)

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT ID: NCT02949284 (https://classic.clinicaltrials.gov/show/NCT02949284)

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT ID: NCT03456843 (https://classic.clinicaltrials.gov/show/NCT03456843)

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT ID: NCT04030559 (https://classic.clinicaltrials.gov/show/NCT04030559)

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT ID: NCT03697148 (https://classic.clinicaltrials.gov/show/NCT03697148)

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT ID: NCT04812366 (https://classic.clinicaltrials.gov/show/NCT04812366)

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
NCT ID: NCT05498272 (https://classic.clinicaltrials.gov/show/NCT05498272)

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT ID: NCT05617885 (https://classic.clinicaltrials.gov/show/NCT05617885)


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.